In a separate group of animals injected with the Bcan-Ntrk1 tumour cells, immunostainings performed after 2 days of treatment with entrectinib revealed a strong decrease in Akt phosphorylation at Serine 473, confirming inhibition of TrkA signalling in vivo (Fig. 4f). Here, NTRK1 is linked to neoplasm.